Key Customers

Key Customers


Dr. Florence Lhospice

Director of the Antibody-Drug Conjugate Program at Innate Pharma
“MImAbs is responsible for developing Innate Pharma’s antibody-drug conjugates. MImAbs can generate, engineer and produce antibodies to specific targets, validate these targets for use with ADCs and develop all the in vitro and in vivo models required, all within a highly flexible process from the earliest stages of antibody development.”

Prof. Rene Hoet

CSO ImCheck Therapeutics
“For screening and development of our novel therapeutic antibodies it is critical to have high quality antibodies to evaluate the effects on different immune cells. We are delighted with the high quality of the different antibodies delivered by MImAbs to us and plan to continue to work with MImAbs in the future as part of our new discovery programs.”

Dr. Jack Elands

CEO Talix Therapeutics
“Talix Therapeutics has been working with MImAbs since its incorporation and MImAbs has become a strategic partner of the company. As such MImAbs has been providing mAb engineering expertise for all aspects of mAb development as well as all determinations around the activation of NK cells.  MImAbs is professionally organized, is very efficient, delivers high quality work and is very cost effective."

Key Partners



    From science to health


   Center for Immunophenomics (CIPHE)

    Generation of knock-in mouse models & Immunophenotyping

MImAbs is a member of :

   Eurobiomed, the catalyst of the health sector in Southern France
   Mabdesign, the French therapeutic antibody and immunotherapy network
   France Biotech, biotech | medtech | e-santé | IA, Les entrepreneurs de la healthtech